24 Ago 2021 | News
During the development of TP-102 a lot of journals published pieces describing this great Technophage’s milestone. This year, Jornal Expresso, described the efforts made by the company to reach Phase I/IIa Clinical Trial with TP-102 in Israel. If you did not get...
20 Ago 2021 | News
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2021’. COTEC Portugal is the main Portuguese business association for the promotion of business innovation and technological cooperation. The COTEC...
4 Ago 2021 | News
During this last year, Technophage has been dedicated to the development of a new biologic product for COVID-19. The company has been working together with Medinfar Group in a joint effort to make available a new biologic that will help to tackle this devastating...
2 Jul 2021 | News
Technophage’s CEO, Miguel Garcia, attended the “Encontro Ciência 2021” in the last 30 of June, speaking about the company’s journey at the plenary session “A ciência cura: desafios e oportunidades da interação ciência-saúde”. This...
11 Mai 2021 | News
In the past few months, and due to the recently initiated Phase I/IIa Clinical Trial of the bacteriophage cocktail TP-102, which has been entirely developed in the company for the treatment of diabetic foot ulcers infected by Pseudomonas aeruginosa, Acinetobacter...
27 Abr 2021 | News
Technophage has been recently featured in the TV show ‘Exame Informática’. In this piece, you can quickly learn a bit more about our bacteriophage cocktail TP-102, also gaining an opportunity to a virtual tour of our GMP production unit. TechnoPhage...
